Trends in Molecular Medicine
ReviewApoptosis and colorectal cancer: implications for therapy
Introduction
Colorectal cancer (CRC) is the third most common cause of cancer-related death among men and women in the western world 1, 2. Europe has the highest CRC incidence, with an estimated 412 900 new cases in 2006 [1], closely followed by the USA, which expected 145 290 new CRCs in 2008 [3]. CRC is rare in Asia, Africa and parts of South America. Although no age group is unaffected, the disease occurs mainly in the seventh decade of life. At the time of presentation, ∼40% of patients already have distant metastases. 5-fluorouracil (5-FU)-based chemotherapeutic regimens are the most common treatments for these patients. Although combining 5-FU with irinotecan and oxaliplatin has improved the response rate, chemotherapies are usually not highly effective against disseminated CRC. A new therapeutic strategy is therefore needed for the treatment of advanced or metastatic CRCs.
Progressive inhibition or evasion of apoptosis has been found during the transformation of colorectal epithelium to carcinoma [4], indicating that dysfunction of apoptosis has an important role in colorectal tumorigenesis. When programmed cell death does not occur appropriately in colon, cells that should be eliminated might persist, become immortal and subsequently develop into colorectal tumours. The cytotoxic action of most chemotherapeutic drugs is often mediated by the activation of apoptotic pathways [5]; therefore, any defect, dysfunction or altered expression of genes encoding key apoptotic proteins can produce drug resistance. For example, loss of p53 function by mutation disables apoptosis and accelerates tumour development, and the altered expression of pro-apoptotic B-cell lymphoma (Bcl)-related proteins dramatically changes the sensitivity of cancer cells to chemotherapy [6]. It is apparent that defects in apoptosis underpin both colorectal tumorigenesis and drug resistance. The search for new therapeutic approaches for the management of metastatic colon cancers has led us to revisit apoptosis and its role in colon cancer tumorigenesis. Recent progress in understanding the molecular mechanisms and role of apoptosis in colon cancer development has provided novel targets for therapy. Here, we review studies of the molecular mechanisms of apoptosis in CRC initiation and progression, and evaluate factors that affect and regulate apoptosis in CRC. Furthermore, dysfunctions in apoptotic pathways through which CRC can develop resistance to chemotherapy are discussed, and potential therapeutic targets are suggested. It is hoped that molecular therapies targeting apoptotic pathways might have the potential to provide new approaches for CRC treatment.
Section snippets
Apoptosis in the normal colorectum
Apoptosis has an important role in determining the architecture of normal colonic epithelia and is part of the response to stress [7]. Each colonic crypt contains several thousand differentiated cells and a small number of stem cells. Although there are different views regarding the origin of tumour cells in colonic crypts 8, 9, colonic stem cells are predominantly found at the bottom of the crypts and divide slowly [10]. Differentiated cells divide rapidly and travel to the top of the crypt;
Apoptosis and colorectal carcinogenesis
The transformation of colorectal epithelium to carcinoma is associated with a progressive inhibition of apoptosis [16], and usually proceeds through a series of pathological progressions to produce colorectal polyps, adenomas, adenoma-containing carcinomas and adenocarcinomas [17]. Examination of the cellular proliferation and apoptosis levels in these processes has shown that both increased proliferation and decreased apoptosis occur during CRC development [18]. The APC and β-catenin pathway
Transforming growth factor-β
Transforming growth factor-β (TGF-β) is a member of a growth factor superfamily that regulates cellular proliferation, differentiation, apoptosis and extracellular matrix formation [38]. TGF-β acts as a tumour suppressor in the normal colon by inhibiting cell proliferation and inducing apoptosis [39]. Disruption of TGF-β signalling is predominantly due to mutational inactivation of the TGF-β receptor (TGFBR2) that occurs in ∼30% of CRC [40]. The mechanism of TGF-β-induced apoptosis has not been
Apoptosis and chemoresistance in CRCs
Even after chemotherapy, metastases can still spread owing to cancer cell resistance. This is a major contributor to the limited effectiveness of current chemotherapeutic drugs. Cancer cells use many mechanisms to protect themselves against the damaging effects of chemotherapeutic agents. For instance, some cancer cells can reduce intracellular drug accumulation by increasing drug efflux from cells and decreasing drug influx. Some cancer cells can reduce drug-related damage by modifying drug
New strategies for the development of CRC treatments
Although not all conventional drugs have been designed to induce apoptosis directly, most of these agents do in fact kill cancer cells through apoptotic pathways, either directly or indirectly. Drugs that directly induce apoptosis have several advantages over those that do not directly cause apoptosis. First, apoptosis results in removal of dead cells in an inconspicuous way, involving phagocytosis by neighbouring cells or specialized macrophage-like cells without producing inflammation and
Concluding remarks
Alteration or suppression of apoptosis has an important role in CRC initiation and development. Aberration of intrinsic apoptotic components, mutation of tumour suppressor genes, modification of COX-2 and PGE2, NF-κB pathways and dependence receptors all contribute to the suppression of apoptosis in CRC development. Targeting these molecules and pathways to induce cancer cell death might offer an alternative approach for treating CRC with the potential advantages of specifically targeting
Glossary
- Intrinsic apoptotic pathway
- the activation of programmed cell death by intracellular signals that are mediated by the Bcl protein family, resulting in the release of cytochrome c from the mitochondrial membrane, and the subsequent activation of caspase-9 and downstream effectors caspases, such as caspase-3 and -7.
- Extrinsic apoptotic pathway
- the activation of programmed cell death by interaction between ‘death ligands’ and ‘death receptors’, in which caspase-8 is activated. When death ligands bind
References (82)
Estimates of the cancer incidence and mortality in Europe in 2006
Ann. Oncol.
(2007)- et al.
The hallmarks of cancer
Cell
(2000) Apoptosis: A link between cancer genetics and chemotherapy
Cell
(2002)Apoptosis of human intestinal epithelial cells after bacterial invasion
J. Clin. Invest.
(1998)Survivin and molecular pathogenesis of colorectal cancer
Lancet
(2003)The Bcl-w promoter is activated by β-catenin/TCF4 in human colorectal carcinoma cells
Gene
(2009)Down-regulation of FHIT inhibits apoptosis of colorectal cancer: mechanism and clinical implication
Surg. Oncol.
(2006)- et al.
Suppression of apoptosis, crypt hyperplasia, and altered differentiation in the colonic epithelia of bak-null mice
Gastroenterology
(2009) Activation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosis
Biochem. Pharmacol.
(2008)Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression
Cancer Cell
(2004)
Making the case for DCC and UNC5C as tumor-suppressor genes in the colon
Gastroenterology
Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer
Gastroenterology
Mechanisms of TGF-β signaling from cell membrane to the nucleus
Cell
Keeping order in the neighborhood: new roles for TGFβ in maintaining epithelial homeostasis
Cancer Cell
Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models
Growth Horm. IGF Res.
Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor
Gastroenterology
The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence
Gastroenterology
Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer
Eur. J. Cancer
Reduced expression of transforming growth factor β type I receptor contributes to the malignancy of human colon carcinoma cells
J. Biol. Chem.
Cancer statistics, 2007
CA Cancer J. Clin.
Cancer Facts and Figures 2008
Dysregulation of apoptosis in cancer
J. Clin. Oncol.
Lessons from genetically engineered animal models. VII. Apoptosis in intestinal epithelium: lessons from transgenic and knockout mice
Am. J. Physiol. Gastrointest. Liver Physiol
Top-down morphogenesis of colorectal tumors
Proc. Natl. Acad. Sci. U. S. A.
Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission
Cancer Res.
Expansion of a mutated clone: from stem cell to tumour
J. Clin. Pathol.
The significance of unstable chromosomes in colorectal cancer
Nat. Rev. Cancer
Intrinsic resistance to apoptosis of colon epithelial cells is a potential determining factor in the susceptibility of the A/J mouse strain to dimethylhydrazine-induced colon tumorigenesis
Mol. Carcinog.
Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors
Proc. Natl. Acad. Sci. U. S. A.
Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells
Cancer Res.
Inhibition of apoptosis during development of colorectal-cancer
Cancer Res.
Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis
Clin. Cancer Res.
Proliferation and apoptosis in proliferative lesions of the colon and rectum
Virchows Arch.
Wnt signalling in stem cells and cancer
Nature
The BCL-2 protein family: opposing activities that mediate cell death
Nat. Rev. Mol. Cell Biol.
Down-regulation of Bax-interacting factor-1 in colorectal adenocarcinoma
Cancer
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment
J. Clin. Oncol.
Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas
Proc. Natl. Acad. Sci. U. S. A.
The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment
Carcinogenesis
Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials
Prog. Exp. Tumor Res.
Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models
Cancer Res.
Cited by (96)
Chitinase domain containing 1 increase is associated with low survival rate and M0 macrophages infiltrates in colorectal cancer patients
2022, Pathology Research and PracticeCell Death, by Any Other Name…
2024, Cells